1. Scrip
  2. >>Business

AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads

 
• By Jung Won Shin

Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Dong-A ST Co. Ltd. has reached a co-development and licensing agreement with AbbVie Biotechnology, a subsidiary of AbbVie Inc., for the South Korean pharma firm's early stage Mer tyrosine kinase inhibitor candidate, in an alliance potentially worth up to $525m plus sales royalties.

Under the deal, Dong-A ST and AbbVie will jointly develop the still preclinical stage molecule until submission of an IND...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.

Incretin Revolution: Obesity And Diabetes Drugs Redefine Pharma’s Sales Leaders

 
• By Edwin Elmhirst

By 2030, the pharmaceutical company leaderboard will be transformed as incretin-based therapies propel Eli Lilly and Novo Nordisk to the top, while companies reliant on aging blockbuster drugs see their dominance wane.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

More from Scrip

Executives On The Move: Instylla And Geron Get New CEOs

Recent moves in the industry include changes at the top at Meitheal Pharmaceuticals, Ardelyx and AIRNA, plus five companies get new CMOs.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead

 
• By Mandy Jackson

Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.